Michael Dillen News Today

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on October 27, 2023, from Atlas Spe...

25.10.2023 - Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal ...

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV , a biopharmaceutical company developing next-generation standard of care ophthalmic...

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LL...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s we...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 27, 2023 – 7.00 PM CET Oxurion NV , a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...

EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 5 of funding under the Subscription Agreement with Atlas Special Opportunities LL...

Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on September 14, 2023, from Atlas...

Regulated Information – Inside Information Waives Key Conditions for Up to €3.5 Million in Atlas FundingReduces Cash Covenant and Total Debt for Kreos/Pontifax Loan Leuven, BELGIUM,...